
    
      The study is a single-center, double-blinded randomized, parallel, non-inferiority trial.
      Patients will be recruited from out-patient clinic, Department of Ophthalmology, Ramathibodi
      Hospital, Bangkok and will be randomized to receive either 100% APRP or 100% AS eye drops
      (1:1 ratio) for 4 weeks. The primary outcomes include ocular surface disease index (OSDI) and
      ocular surface staining evaluated using the Oxford scale. Secondary outcomes are fluorescein
      break-up time (FBUT), Schirmer's I test (ST I), meibomian gland parameters and adverse
      events.
    
  